Diagnosis -- Germline GATA2 Mutation in Myelodysplasia-related Acute Myeloid Leukemia


SUMMARY and DISCUSSION

The protein product of the GATA2 gene is a transcription factor with two DNA-binding zinc finger domains. This protein plays a significant role in the induction and expansion of hematopoietic stem cells (HSCs) during fetal development and in proliferation of HSCs in later life [6]. While the specific mechanisms of leukemogenesis in GATA2 deficiency are not completely understood, pathogenic mutations are thought to cause loss of one of the zinc finger domains present in GATA2, thereby inhibiting or altering its interactions with DNA [7, 8].

In this case, whole genome CGH+SNP microarray results were suggestive of a constitutional (germline) loss of 3q21.3, corresponding to the area of the chromosome containing the GATA2 gene (Figure 1F). Germline mutations in the GATA2 gene have been detected in up to 7% of pediatric MDS cases, reaching a prevalence of 72% in pediatric MDS with monosomy 7, as was present in our case [7]. The identification of germline mutations is a finding of particular significance for patients, as these mutations can be inherited and may be present in other family members.

Additional mutations were identified using next-generation sequencing in this case, including ETV6, EZH2, ASXL1, and SETBP1. ETV6 encodes a transcription factor which has an important role in regulation of hematopoiesis and whose alterations have been implicated in the development of several hematologic malignancies [9]. The products of the ASXL1 and EZH2 genes are involved in epigenetic regulation of stem cell differentiation via histone methylation, and mutations in these two genes are commonly seen in MDS [10]. SETBP1 codes for a proto-oncogene whose overexpression is frequently present in AML. The presence of SETBP1 mutation is also associated with mutations in ASXL1 and EZH2. Each of these mutations is independently associated with poor prognosis in MDS and/or AML [10, 11].

Conventional karyotyping can also be an important source of prognostic information, not only by identifying specific prognostically useful chromosomal abnormalities within a neoplasm, but also by demonstrating clonal evolution and/or the presence of subclones. Both clonal evolution and subclones are associated with progression of MDS to AML, as well as with poor prognosis for patients already diagnosed with AML [12]. In this case, two abnormal clones were detected on conventional karyotyping, one clone with monosomy 7 and a subclone with both monosomy 7 and trisomy 8.

Regarding treatment of MDS and AML, HSCT is the only curative therapy. HSCT may utilize a related donor, although in the case of a patient with a germline mutation, testing the relative for the presence of the same mutation should be considered, in order to avoid transplanting tissue with a similar potential for neoplastic transformation. In this case, however, the patient received a transplant from an unrelated donor. Following HSCT, overall survival rates in patients with germline GATA2 mutations are reportedly similar to those of patients without such mutations, although the incidence of transplant-related neurological toxicity and thrombotic events may be increased [13].

REFERENCES

  1. Adčs L MD, Itzykson R MD, Fenaux P Prof. Myelodysplastic syndromes. Lancet Br Ed. 2014;383(9936):2239-2252. doi:10.1016/S0140-6736(13)61901-7
  2. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45-52. doi:10.1182/blood-2008-01-134858
  3. Bezerra MF, Larrazábal BR, Lima AS, et al. Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes. Hematol Transfus Cell Ther. Published online January 3, 2021. doi:10.1016/j.htct.2020.10.967
  4. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-4395. doi:10.1182/blood-2007-03-082404
  5. Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154(2):185-195. doi:10.1111/j.1365-2141.2011.08724.x
  6. Ling K-W, Ottersbach K, van Hamburg JP, et al. GATA-2 Plays Two Functionally Distinct Roles during the Ontogeny of Hematopoietic Stem Cells. J Exp Med. 2004;200(7):871-882. doi:10.1084/jem.20031556
  7. Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127(11):1387-1397. doi:10.1182/blood-2015-09-669937
  8. Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood. 2011;118(10):2656-2658. doi:10.1182/blood-2011-06-360313
  9. Wang Q, Dong S, Yao H, et al. ETV6 mutation in a cohort of 970 patients with hematologic malignancies. Haematologica. 2014;99(10):e176-e178. doi:10.3324/haematol.2014.104406
  10. Bravo GM, Lee E, Merchan B, Kantarjian HM, García-Manero G. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. Br J Haematol. 2014;166(5):646-659. doi:10.1111/bjh.12957
  11. Hou H-A, Kuo Y-Y, Tang J-L, et al. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression. Am J Hematol. 2014;89(2):181-186. doi:10.1002/ajh.23611
  12. Neukirchen J, Lauseker M, Hildebrandt B, et al. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis. Cancer. 2017;123(23):4608-4616. doi:10.1002/cncr.30917
  13. Hofmann I, Avagyan S, Stetson A, et al. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations. Biol Blood Marrow Transplant. 2020;26(6):1124-1130. doi:10.1016/j.bbmt.2020.02.015


Contributed by Gabe Sexton, MD and Svetlana Yatsenko, MD




Case IndexCME Case StudiesFeedbackHome